Finally, it appears all but certain that we shall have a swine-origin H1N1 influenza vaccine sometime in the fall.
Seed strains developed at CDC are now in the hands of manufacturers and both Sanofi -Pasteur and GlaxoSmithKline
have announced government contracts to produce a vaccine. Unfortunately, we are still a year or two away from using a tissue culture based production technology; hence, we must continue to rely on egg-based production.
October and November seems a reasonable target date, with a possibility of some doses being available in September.
More likely than not, it will be a two-dose series, perhaps with adjuvant added as an antigen-sparing measure. It
is not at all clear how this vaccine will be integrated with seasonal vaccine administration.